Pancreatic neuroendocrine neoplasms (panNENs) are heterogeneous neoplasms with
neuroendocrine differentiation that show characteristic clinical, histomorphologic, and …

The traditionally promulgated perspectives of neuroendocrine neoplasms (NEN) as rare,
indolent tumours are blunt and have been outdated for the last 2 decades. Clear increments …

Distinguishing grade 3 pancreatic neuroendocrine tumor (G3 PanNET) from neuroendocrine
carcinoma (PanNEC) is a known diagnostic challenge, and accurate classification is critical …

Peptide receptor radionuclide therapy (PRRT) is a type of radiotherapy that targets peptide
receptors and is typically used for neuroendocrine tumours (NETs). Some of the key …

The majority of high-risk neuroblastomas can be divided into three distinct molecular
subgroups defined by the presence of MYCN amplification, upstream TERT rearrangements …

Pancreatic neuroendocrine tumors (PanNENs) are rare sporadic cancers or develop as part
of hereditary syndromes. PanNENs can be both functioning and non-functioning based on …

Peptide receptor radionuclide therapy (PRRT) is a paradigm shifting approach to the
treatment of neuroendocrine tumors. Although there are no prospective randomized trials …

Well differentiated neuroendocrine tumors (NETs) arising in the gastrointestinal and
pancreaticobiliary system are the most common neuroendocrine neoplasms. Studies of the …

Some biomarkers for functioning and non-functioning neuroendocrine neoplasms (NENs)
are currently available. Despite their application in clinical practice, results should be …

Pancreatic neuroendocrine neoplasms (pNENs) are rare cancers with broad challenges for
their management. The main clinical obstacles are the high rate of patients diagnosed at …